Bibliografie tematiche / Cisplatin / Libri

Libri sul tema "Cisplatin"

Segui questo link per vedere altri tipi di pubblicazioni sul tema: Cisplatin.
Autore: Grafiati
Pubblicato: 4 giugno 2021
Ultima modifica: 6 luglio 2024

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 libri per l'attività di ricerca sul tema "Cisplatin".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi i libri di molte aree scientifiche e compila una bibliografia corretta.

1

Ozols, Robert F. High-dose Platinol (cisplatin for infection) in hypertonic saline. Syracuse, N.Y: Bristol-Myers Oncology Division, 1985.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Chu, Wendy. Mechanism of cisplatin resistance inhuman malignant melanoma. Ottawa: National Library of Canada, 1998.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Yoshihiro, Kikuchi, a cura di. Mechanism of cisplatin resistance and its circumvention. Commack, NY: Nova Science Publishers, 1998.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Merazga, Yamina. Aspects of the interaction between cisplatin and renal glutathione. Uxbridge: Brunel University, 1990.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

1946-, Lippert Bernhard, a cura di. Cisplatin: Chemistry and biochemistry of a leading anticancer drug. Zürich: Verlag Helvetica Chimica Acta, 1999.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Morley, Christopher. Analogues of cisplatin from diamino carbohydrates and related compounds. Norwich: University of East Anglia, 1986.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Evans, Dyfed Llyr. The induction of apoptosis by the anticancer agent cisplatin. Manchester: Universityof Manchester, 1994.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Laurell, Göran. Ototoxicity of the anticancer drug cisplatin: Clinical and experimental aspects. Stockholm, Sweden: Distributed by Almqvist & Wiksell Periodical Co., 1991.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Pembrolizumab (nicht kleinzelliges Lungenkarzinom: Nutzenbewertung gemäß § 35a SGB V. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, 2017.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Bryant, Eric Edward. Systems Genetics of DNA Damage Tolerance – Cisplatin, RAD5 & CRISPR-mediated Nonsense. [New York, N.Y.?]: [publisher not identified], 2019.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
11

Kuduk-Jaworska, Janina. Przeciwnowotworowo aktywne kompleksy platyny. Wrocław: Wydawn. Uniwersytetu Wrocławskiego, 1992.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
12

International, Congress on Neo-Adjuvant Chemotherapy (2nd 1987 Paris France). Paraplatine: Carboplatine: symposium satellite du deuxième congrès international sur la chimiothérapie néo-adjuvante Paris, 20 frévier 1988. Paris: Libbey Eurotext, 1988.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
13

M, Beard S., e Trent Institute for Health Services Research. Working Group on Acute Purchasing., a cura di. The use of cisplatin and paclitaxel as a first line treatment in ovarian cancer. Sheffield: Trent Institute for Health Services Research, 1997.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
14

Kuzniar, Beata. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity. Ottawa: National Library of Canada, 1998.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
15

Weinrib, Laura M. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and -negative nasopharyngeal carcinoma. Ottawa: National Library of Canada, 2000.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
16

Obasaju, Coleman Kehinde. Methotrexate and cisplatin pharmacokinetics when used as neoadjuvant treatment in patients with poor progress cervical cancer. Manchester: University of Manchester, 1995.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
17

Malinowski, Jerzy. Sztuka i nowa wspólnota: Zrzeszenie Artystów Bunt, 1917-1922. Wrocław: "Wiedza o Kulturze", 1991.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
18

H, McBrien D. C., e Slater T. F, a cura di. Biochemical mechanisms of platinum antitumour drugs: Based on the proceedings of a symposium held at Brunel University, 3-5th July 1985. Oxford: IRL, 1986.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
19

H, McBrien D. C., e Slater T. F. 1931-, a cura di. Biochemical mechanisms of platinum antitumour drugs: Based on the proceedings of a symposium held at Brunel University, July 3-5, 1985. Oxford: IRL, 1986.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
20

Souzamotta, Nando. Cisplatino versus Mandinga! Montevideo: Zignone Comics, 2011.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
21

Cabrelli, Matias. Presencia masónica en la Cisplatina. [Montevideo]: América Una, 1986.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
22

Cabrelli, Alfonso Fernández. Presencia masónica en la Cisplatina. [Montevideo]: América Una, 1986.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
23

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (5th 1987 Padua, Italy). Platinum and other metal coordination compounds in cancer chemotherapy: Proceedings of the Fifth International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, Abano Padua, Italy, June 29-July 2, 1987. Boston: Nijhoff, 1988.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
24

R, Kelland Lloyd, e Farrell Nicholas 1948-, a cura di. Platinum-based drugs in cancer therapy. Totowa, N.J: Humana Press, 2000.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
25

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (7th 1995 Amsterdam, Netherlands). Platinum and other metal coordination compounds in cancer chemotherapy 2. New York: Plenum Press, 1996.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
26

International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy (6th 1991 San Diego, Calif.). Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press, 1991.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
27

Barroso, Gustavo. A Guerra do Vidéo: 1825-1828 : contos e episódios da Campanha da Cisplatina. [Fortaleza, Brazil]: UFC, Casa de José de Alencar, Programa Editorial, 2000.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
28

Canez, Anna Paula. Arquiteturas cisplatinas: Roman Fresnedo Siri e Eladio Dieste em Porto Alegre. Porto Alegre, RS: UniRitter, Centro Universitário Ritter dos Reis, Faculdade de Arquitetura e Urbanismo, 2004.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
29

Lippert, Bernhard, a cura di. Cisplatin. Wiley, 1999. http://dx.doi.org/10.1002/9783906390420.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
30

Brock, Patrick. Cisplatin Toxicity in Infants and Children. Leuven University Press, 1994.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
31

Prestayko, Archie W. Cisplatin: Current Status and New Developments. Elsevier Science & Technology Books, 2013.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
32

Kojima, Toshiko, e Yoko Morita. Cisplatin: Pharmacology, Clinical Uses and Adverse Effects. Nova Science Publishers, Incorporated, 2012.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
33

Bongers, Jacob. Platinum(II) metallothioneins. 1989.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
34

Lippert, Bernhard. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Wiley-VCH, 1999.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
35

Lippert, Bernhard. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Wiley & Sons, Limited, John, 2006.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
36

Publications, ICON Health. Cisplatin - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References. ICON Health Publications, 2004.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
37

Clinical and Preclinical Pharmacokinetic and Dynamic Studies with Cisplatin, Topotecan and Docetaxel. ICG Printing, 1996.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
38

Ajithkumar, Thankamma, Ann Barrett, Helen Hatcher e Natalie Cook. Appendix. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235636.003.0022.

Testo completo
Abstract (sommario):
Systemic therapy regimens 692Radiotherapy fractionation 695Glomerular filtration rate 701Anatomical diagrams 702• Cisplatin 80–100mg/m2 IV infusion Day 1• 5-FU 1g/m2 24-hour infusion Days 1–5• 3-week cycle• 75mg/m2 for 42 days starting on the first day of radiotherapy. Give 1 hour prior to radiotherapy and morning at weekend...
Gli stili APA, Harvard, Vancouver, ISO e altri
39

Pinkett, Georgia L. Cisplatinum: An antineoplastic agent with an ototoxic effect. 1991.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
40

McBrien, D. C. H. Biochemical Mechanisms of Platinum Antitumour Drugs. Oxford University Press, USA, 1985.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
41

(Editor), Lloyd R. Kelland, e Nicholas P. Farrell (Editor), a cura di. Platinum-Based Drugs in Cancer Therapy (Cancer Drug Discovery and Development). Humana Press, 2000.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
42

(Editor), Donald Henderson, Richard J. Salvi (Editor), Antonio Quaranta (Editor) e et al (Editor), a cura di. Ototoxicity: Basic Science and Clinical Applications (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1999.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
43

Calabrò, Fabio, e Cora N. Sternberg. Treatment of metastatic bladder cancer. A cura di James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0079.

Testo completo
Abstract (sommario):
Although bladder cancer is considered a chemosensitive malignancy, the prognosis of patients with metastatic disease is poor, with a median survival of approximately 12–14 months in good prognosis patients and with cure in only a minority. The addition of new drugs to the standard cisplatin-based regimens has not improved these outcomes. In this chapter, we highlight the role of chemotherapy and the impact of the new targeted agents in the treatment of metastatic bladder carcinoma. A better understanding of the underlying biology and the molecular patterns of urothelial bladder cancer has led to clinical investigation of several therapeutic targets. To date, these agents have yet to demonstrate an improvement in overall survival. Urothelial cancer is extremely sensitive to checkpoint inhibition with both anti PD-1 and anti PDL1 antibodies. The future seems brighter with the advent of these new therapies.
Gli stili APA, Harvard, Vancouver, ISO e altri
44

Ball, Steve, e Sajid Kalathil. Adrenocortical cancer. A cura di James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0094.

Testo completo
Abstract (sommario):
Adrenocortical cancer (ACC) is rare and associated with poor prognosis. The incidence is estimated at 0.7–2 cases per one million. Overall survival rate at five years for ACC is 37–47%. While the pathogenesis of ACC is incompletely understood, inherited predisposition syndromes are common in childhood ACC. Clinical presentation can be with symptoms and signs of hormone excess (functional tumours), mass effects, or as an incidental radiological finding. A multidisciplinary approach combining radiology, biochemistry, and tissue-based pathology is needed to establish a diagnosis to guide a surgical approach aimed at complete resection of the tumour where possible. At present, recommended first-line therapies for advanced disease are mitotane monotherapy or etopiside, doxorubicin, and cisplatin plus mitotane. Metronomic capecitabine and gemcitabine have been used as alternatives. Adjuvant radiotherapy to the tumour bed should be considered for patients considered to be at high risk of recurrence.
Gli stili APA, Harvard, Vancouver, ISO e altri
45

Hoskin, Peter. Vulva and vagina. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199696567.003.0014.

Testo completo
Abstract (sommario):
Chapter 9b discusses carcinoma of the vulva, which is primarily a surgical disease best treated by wide surgical resection, radical vulvectomy, and inguinal lymph node dissection based on presenting stage. Rarely, locally advanced primary disease may be presented for primary radiotherapy treatment. Postoperative radiotherapy is recommended for tumours invading >7 mm in a vertical direction. The first station regional lymph nodes in the inguinal region are best treated by radical surgical dissection, but fixed inoperable lymph nodes may benefit from primary radiotherapy which may be followed where appropriate by surgery if there is a residual mass. Postoperative radiotherapy should be considered for women having more than one node involved with metastatic tumour at surgery. This must be balanced against the increased risk of lymphoedema where both surgery and radiotherapy are delivered to the groins. Chemoradiation using cisplatin or 5-FU/mitomycin C-based schedules has been reported but no randomized comparison with radiotherapy alone has been undertaken; whilst high response rates are seen there is a considerable increase in acute toxicity.
Gli stili APA, Harvard, Vancouver, ISO e altri
46

Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy 2. Springer, 1996.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
47

D, Ahlgren James, Rotman Marvin 1933- e Rosenthal C. Julian, a cura di. Concomitant continuous infusion chemotherapy and radiation. Berlin: Springer-Verlag, 1991.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
48

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff e Madhumita Bhattacharyya. Breast cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0014_update_001.

Testo completo
Abstract (sommario):
Thoracic cancer examines the epidemiology, aetiology, and role of screening and prevention in the reduction of deaths from lung cancer, the majority caused by cigarette smoking. The pathology and genetics of lung cancer, with particular note of the driver mutations, are followed by the symptoms and signs of the disease. Appropriate investigations are described to stage the tumour. The optimum treatment for localised non-small cell lung cancer (NSCLC) is surgical resection, followed in some cases by adjuvant chemotherapy. However, most cases present with disease too advanced for surgery, and for these chemotherapy and radiotherapy are appropriate. Metastatic NSCLC can be treated with platinum based doublet chemotherapy with modest palliative benefits. Metastatic NSCLC with specific driver mutations are amenable to control by targeted therapy. Locally advanced NSCLC is often treated with similar chemotherapy and radiotherapy, ideally administered concurrently, to achieve symptom relief but also improved survival rates. Short course simple radiotherapy offers symptom relief in patients not fit for chemotherapy. Patients with localised NSCLC who are not fit for surgery, may benefit from radical radiotherapy, particularly stereotactic radiotherapy. Small cell lung cancer (SCLC) is characterised by almost universal systemic spread, so that surgery is rarely appropriate. Staging is similar to NSCLC, and chemotherapy is the mainstay of treatment, usually cisplatin or carboplatin combined with etoposide. When possible, this is combined with concurrent thoracic irradiation covering all radiological sites of disease. Prophylactic cranial irradiation reduces the risk of CNS disease. Malignant pleural mesothelioma is caused by occupational asbestos exposure. Symptoms and signs, investigation and staging, and management are discussed. Thymic tumours, their pathology, presenting symptoms including paraneoplastic syndromes, investigation, staging and treatment are reviewed.
Gli stili APA, Harvard, Vancouver, ISO e altri
49

Brady, L. W., C. Julian Rosenthal, Marvin Rotman e H. P. Heilmann. Concomitant Continuous Infusion Chemotherapy and Radiation. Springer London, Limited, 2012.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
50

Brady, L. W., C. Julian Rosenthal, Marvin Rotman e H. P. Heilmann. Concomitant Continuous Infusion Chemotherapy and Radiation. Springer London, Limited, 2012.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
Ti possono interessare anche gli elenchi di altri tipi di fonti sul tema "Cisplatin":
Articoli di riviste Tesi
Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!

Vai alla bibliografia